Predicting Progression to Mild Cognitive Impairment
© 2018 American Neurological Association Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.
Annals of Neurology
Digital Object Identifier (DOI)
Petersen, Ronald C.; Lundt, Emily S.; Therneau, Terry M.; Weigand, Stephen D.; Knopman, David S.; Mielke, Michelle M.; Roberts, Rosebud O.; Lowe, Val J.; Machulda, Mary M.; Kremers, Walter K.; Geda, Yonas E.; and Jack, Clifford R., "Predicting Progression to Mild Cognitive Impairment" (2019). Neurology. 347.